Page 146 - Read Online

Bale et al. Hepatoma Res 2023;9:44 https://dx.doi.org/10.20517/2394-5079.2023.71 Page 11 of 13

PubMed
18. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised
trials. Ann Oncol 2014;25:391-8. DOI
19. Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive
patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol 2022;7:522-32.
DOI PubMed
20. Rizzo A, Brandi G. First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "and yet it moves!
Cancer Treat Res Commun 2021;27:100335. DOI PubMed
21. Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine
and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020;6:60-7. DOI
PubMed PMC
22. Zhou TY, Zhou GH, Zhang YL, et al. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for
treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer 2020;11:4534-41. DOI PubMed PMC
23. Gupta AN, Gordon AC, Gabr A, et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term
follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol 2022;45:1117-28. DOI
24. Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 Radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a
multicenter retrospective study. Cardiovasc Intervent Radiol 2020;43:1305-14. DOI
25. Jonczyk M, Collettini F, Schnapauff D, et al. Cholangiocarcinoma: CT-guided high-dose rate brachytherapy (CT-HDRBT) for limited
(<4 cm) and large (>4 cm) tumors. Anticancer Res 2018;38:5843-52. DOI PubMed
26. Owen M, Makary MS, Beal EW. Locoregional therapy for intrahepatic cholangiocarcinoma. Cancers 2023;15:2384. DOI PubMed
PMC
27. Franssen S, Soares KC, Jolissaint JS, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with
multifocal intrahepatic cholangiocarcinoma. JAMA Surg 2022;157:590-6. DOI PubMed PMC
28. Brandi G, Rizzo A, Dall'Olio FG, et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective
single-center experience. Int J Hyperthermia 2020;37:479-85. DOI
29. Xiang X, Hu D, Jin Z, Liu P, Lin H. Radiofrequency ablation vs. surgical resection for small early-stage primary intrahepatic
cholangiocarcinoma. Front Oncol 2020;10:540662. DOI PubMed PMC
30. Bale R, Schullian P, Haidu M, Widmann G. [Stereotactic radiofrequency ablation (SRFA) of intrahepatic cholangiocellular
carcinomas: a minimal invasive alternative to liver resection]. Wien Med Wochenschr 2013;163:128-31. DOI PubMed
31. Haidu M, Dobrozemsky G, Schullian P, et al. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a
retrospective study. Cardiovasc Intervent Radiol 2012;35:1074-82. DOI
32. Sweeney J, Parikh N, El-Haddad G, Kis B. Ablation of intrahepatic cholangiocarcinoma. Semin Intervent Radiol 2019;36:298-302.
DOI PubMed PMC
33. Lubner MG, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc
Interv Radiol 2010;21:S192-203. DOI PubMed PMC
34. Lee SM, Ko HK, Shin JH, Kim JH, Chu HH. Combination of intraoperative radiofrequency ablation and surgical resection for
treatment of cholangiocarcinoma: feasibility and long-term survival. Diagn Interv Radiol 2020;26:45-52. DOI PubMed PMC
35. Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:2-6. DOI PubMed PMC
36. Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic
cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015;26:943-8. DOI PubMed
37. Ahmed M, Solbiati L, Brace CL, et al; International Working Group on Image-guided Tumor Ablation; Interventional Oncology Sans
Frontières Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice
Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of
terminology and reporting criteria--a 10-year update. Radiology 2014;273:241-60. DOI PubMed PMC
38. Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg 2002;68:395-7. DOI PubMed
39. Chu HH, Kim JH, Shin YM, Won HJ, Kim PN. Percutaneous radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma
after curative resection: multivariable analysis of factors predicting survival outcomes. AJR Am J Roentgenol 2021;217:426-32. DOI
PubMed
40. Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after
curative resection. Eur J Radiol 2011;80:e221-5. DOI PubMed
41. Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic
cholangiocarcinoma. AJR Am J Roentgenol 2011;196:W205-9. DOI PubMed
42. Carrafiello G, Laganà D, Cotta E, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience.
Cardiovasc Intervent Radiol 2010;33:835-9. DOI
43. Butros SR, Shenoy-Bhangle A, Mueller PR, Arellano RS. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability,
local tumor control, and long-term outcome. Clin Imaging 2014;38:490-4. DOI PubMed
44. Yu MA, Liang P, Yu XL, et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur
J Radiol 2011;80:548-52. DOI
45. Wang X, Liang P, Yu J, et al. Contrast-enhanced ultrasound features predict the prognosis of percutaneous microwave ablation of